Domestic Innovative Drugs Enter Harvest Period: Major Breakthroughs in Brain-Computer Interfaces and Alzheimer's Treatment, Wanjia Hong Kong Stock Connect Innovative Drug ETF (520700) Surges Nearly 2% on Expanded Volume

On March 16, the Hong Kong stock market’s innovative drug sector continued to rise, with Kangfang Biotech up over 5%, CSPC Pharmaceutical, Sino Biopharmaceutical, and Jing Tai Holdings up over 4%, and Cinda Biotech, Legend Biotech, BeiGene, and others also gaining. As of 13:59, the Hong Kong Stock Connect Innovation Drug ETF Wanjia (520700) increased by 1.94%, with a trading volume exceeding 180 million yuan, surpassing the entire previous trading day’s level, indicating active market trading.

Domestic innovative drugs are entering a harvest period. Recently, the National Medical Products Administration approved a registered innovative implantable brain-computer interface system, achieving the world’s first launch of an invasive brain-computer interface medical device. On March 12, the launch meeting for the national major science and technology project “Research on Novel Mechanisms and Chemical Innovative Drugs for Anti-Alzheimer’s Disease” was held in Shanghai.

CICC Securities’ research report pointed out that at the policy level, the “Government Work Report” promotes industrial policy and healthcare system reform simultaneously. On the industrial side, the report explicitly proposes to develop emerging pillar industries such as biomedicine (listed as an emerging industry in 2025), and emphasizes promoting high-quality development of innovative drugs and medical devices. “Innovative drugs” have been included in the “Government Work Report” for the third consecutive year, and future industry priorities such as brain-computer interfaces and embodied intelligence are also incorporated. Coupled with support from “patient capital,” innovative drugs and medical devices are expected to remain key long-term development directions.

The Hong Kong Stock Connect Innovation Drug ETF Wanjia (520700) tracks the CSI Hong Kong Stock Connect Innovation Drug Index, which is constructed in a more scientific and reasonable manner. Its constituent stocks include leading companies such as BeiGene, Cinda Biotech, and WuXi Biologics. It focuses on listed companies involved in the research, production, and services of innovative drugs in the Hong Kong stock market. Off-market investors can explore opportunities in innovative drug development through the connection (Type A: 023481; Type C: 023482).

(Investments involve risks; please proceed with caution.)

(Edited by: He Chong)

【Disclaimer】This article only reflects the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in this article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use this information for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com